The findings were reported in Science Translational Medicine. The researchers wanted to measure autoantibody levels in nasal ...

A wide variety of COVID-19 symptoms exist, ranging from mild to severe, and while current strains of the virus generally cause milder symptoms, those with co-morbidities are still at an exponentially ...

A specific autoantibody signature was seen in a subset of people with multiple sclerosis (MS) long before clinical symptoms ...

Johnson & Johnson announced that the US Food and Drug Administration (FDA) has granted nipocalimab Breakthrough Therapy designation (BTD) for the treatment of adults living with moderate-to-severe ...

Ocular autoimmune disease involves the immune system attacking the tissues of the eye. These diseases typically manifest through an autoantibody response targeting the retina, uvea, vitreous, and ...

The US Food and Drug Administration (FDA) has awarded the second breakthrough therapy designation (BTD) to Johnson & ...

Johnson & Johnson announced that the U.S. Food and Drug Administration has granted nipocalimab Breakthrough Therapy designation for the ...

In addition, markers for inflammation and autoantibody testing (like RF and anti-CCP) are negative in fibromyalgia because ...

Topline results are anticipated in the first half of 2026. The Phase 2b LUMUS program for ESK-001 in SLE is designed to evaluate the efficacy, safety and pharmacokinetics of multiple doses of ESK-001 ...

The world will be celebrating diabetes Day on November 14 under the slogan, "Breaking Barriers, Bridging Gaps," to raise awareness and educate people about the nature of the disease and how to deal ...